Diabetes, obesity, and cardiometabolic CARE · 2026
Benefits and Costs of Treating Obesity Among Adults in Commercial Insurance Plans.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dall Timothy M, Chen Fang, Sapra Tanvi, Ferguson Catherine, Hafida Samar, Livingston Tia, Moody Anna, ElSayed Nuha A, Bannuru Raveendhara R
Аннотация
OBJECTIVE: To evaluate the clinical, economic, and social benefits and costs of evidence-based obesity treatment among commercially insured adults.
RESEARCH DESIGN AND METHODS: Using a Markov-based microsimulation model, we projected 5-year clinical and economic outcomes of intensive lifestyle management, obesity medications, and metabolic/bariatric surgery, drawing on data from clinical trials, national surveys, and economic studies.
RESULTS: This analysis focused on 47.3 million commercially insured adults with obesity who lacked access to treatment through existing clinical pathways. Over 5 years, cumulative medical savings per person ranged from $2,908 for lifestyle intervention to $2,450-$7,304 for obesity medications and $12,001 for surgery among adults without preexisting diabetes or cardiovascular disease. At the population level, access to treatment would yield 5-year benefits of $9.7 billion in medical savings, $25.8 billion in productivity gains, $38.8 billion in quality-of-life value, and $29.6 billion in mortality-reduction benefits, requiring $44.7 billion in total investment. Combined benefits produced net social value of $59.1 billion, with a $2.35 return per dollar invested and positive returns as early as the second year.
CONCLUSIONS: Obesity treatment generates substantial social benefits through improved health outcomes and productivity gains. Medical and disability cost savings and workplace productivity improvements combined could recover 81% of treatment investment. Employees effectively finance coverage through premiums and reduced wages, and comprehensive benefit design that includes health outcomes and quality-of-life improvements more accurately reflects societal treatment value. Coverage decisions based solely on employer economic returns underestimate the full societal value of expanding coverage.
UNLABELLED: Video 1.Video abstract48ed6990-a68e-4467-8080-ab264925c4c6doci250006video1.
RESEARCH DESIGN AND METHODS: Using a Markov-based microsimulation model, we projected 5-year clinical and economic outcomes of intensive lifestyle management, obesity medications, and metabolic/bariatric surgery, drawing on data from clinical trials, national surveys, and economic studies.
RESULTS: This analysis focused on 47.3 million commercially insured adults with obesity who lacked access to treatment through existing clinical pathways. Over 5 years, cumulative medical savings per person ranged from $2,908 for lifestyle intervention to $2,450-$7,304 for obesity medications and $12,001 for surgery among adults without preexisting diabetes or cardiovascular disease. At the population level, access to treatment would yield 5-year benefits of $9.7 billion in medical savings, $25.8 billion in productivity gains, $38.8 billion in quality-of-life value, and $29.6 billion in mortality-reduction benefits, requiring $44.7 billion in total investment. Combined benefits produced net social value of $59.1 billion, with a $2.35 return per dollar invested and positive returns as early as the second year.
CONCLUSIONS: Obesity treatment generates substantial social benefits through improved health outcomes and productivity gains. Medical and disability cost savings and workplace productivity improvements combined could recover 81% of treatment investment. Employees effectively finance coverage through premiums and reduced wages, and comprehensive benefit design that includes health outcomes and quality-of-life improvements more accurately reflects societal treatment value. Coverage decisions based solely on employer economic returns underestimate the full societal value of expanding coverage.
UNLABELLED: Video 1.Video abstract48ed6990-a68e-4467-8080-ab264925c4c6doci250006video1.